(S (NP (DT The) (NML (NN drug) (NN discovery)) (NN stage)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ vital) (NN aspect)) (PP (IN of) (NP (DT the) (NML (NN drug) (NN development)) (NN process))))) (CC and) (VP (VBZ forms) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (JJ initial) (NNS stages)) (PP (IN of) (NP (DT the) (NN development) (NN pipeline)))))))) (. .))
(S (PP (IN In) (NP (JJ recent) (NNS times))) (, ,) (NP (ADJP (NP (NN machine) (NN learning)) (HYPH -) (VBN based)) (NNS methods)) (VP (VBP are) (ADVP (RB actively)) (VP (VBG being) (VP (VBN used) (S (VP (TO to) (VP (VB model) (NP (NML (NN drug) (HYPH -) (NN target)) (NNS interactions)) (PP (IN for) (NP (JJ rational) (NN drug) (NN discovery))) (PP (IN due) (PP (IN to) (NP (NP (DT the) (JJ successful) (NN application)) (PP (IN of) (NP (NP (DT these) (NNS methods)) (PP (IN in) (NP (JJ other) (NNS domains)))))))))))))) (. .))
(S (PP (IN In) (NP (NML (NN machine) (NN learning)) (NNS approaches))) (, ,) (NP (NP (DT the) (JJ numerical) (NN representation)) (PP (IN of) (NP (NNS molecules)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN to) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (DT the) (NN model))))))) (. .))
(S (SBAR (IN While) (S (NP (JJ significant) (NN progress)) (VP (VBZ has) (VP (VBN been) (VP (VBN made) (PP (IN in) (NP (JJ molecular) (NN representation) (NN engineering)))))))) (, ,) (NP (DT this)) (VP (VBZ has) (VP (VBN resulted) (PP (IN in) (NP (NP (JJ several) (NNS descriptors)) (PP (IN for) (NP (DT both) (NNS targets) (CC and) (NNS compounds))))))) (. .))
(S (ADVP (RB Also)) (, ,) (NP (NP (DT the) (NN interpretability)) (PP (IN of) (NP (NN model) (NNS predictions)))) (VP (VBZ is) (NP (NP (DT a) (JJ vital) (NN feature)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB have) (NP (JJ several) (JJ pharmacological) (NNS applications)))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (ADJP (NP (NN self) (HYPH -) (NN attention)) (HYPH -) (VBN based)) (JJ multi-view) (NN representation) (NN learning) (NN approach)) (PP (IN for) (NP (VBG modeling) (NML (NN drug) (HYPH -) (NN target)) (NNS interactions))))) (. .))
(S (NP (PRP We)) (VP (VBD evaluated) (NP (PRP$ our) (NN approach)) (UCP (S (VP (VBG using) (NP (CD three) (NN benchmark) (NN kinase) (NNS datasets)))) (CC and) (PP (VBN compared) (NP (NP (DT the) (JJ proposed) (NN method)) (PP (IN to) (NP (DT some) (NN baseline) (NNS models))))))) (. .))
(S (NP (PRP$ Our) (JJ experimental) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (PRP$ our) (NN method) (S (VP (TO to) (VP (VB achieve) (NP (NP (JJ competitive) (NN prediction) (NN performance)) (CC and) (NP (NN offer) (ADJP (RB biologically) (JJ plausible)) (NML (NN drug) (HYPH -) (NN target)) (NN interaction) (NNS interpretations)))))))))) (. .))
